In addition, minocycline, which inhibits hypoxic microglial activation in vitro, protects astrocytes and endothelial cells against hypoxic cell death in vitro and protects the brain against BBB disruption after stroke in vivo [52], and mice with genetic deletion of Cx3Cr1, which is expressed by microglia and not neurons and astrocytes in the brain parenchyma, have altered microglial behavior and less BBB disruption after stroke [51, 53]. The gene discussed is CX3CR1; the disease is stroke disorder.